Education
About Us
Working with TipRanks
Follow Us
Amoeba SA (FR:ALMIB)
:ALMIB
Top Page
Amoeba SA
(ALMIB)
Select Model
Select Model
Rating:41Neutral
Price Target:
€1.00
▼(-7.41% Downside)
Action:ReiteratedDate:11/19/25
The overall stock score is heavily influenced by significant financial challenges, including persistent losses and liquidity issues. Technical analysis suggests bearish momentum, and valuation metrics are unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall score.
Positive Factors
Innovative Product Line
Amoeba's focus on microbial solutions for agriculture positions it well in the growing market for sustainable farming practices, offering a competitive edge.
Strategic Partnerships
Partnerships enhance market reach and distribution, supporting revenue growth and expanding the customer base in the agricultural sector.
Government Support
Government support through subsidies and grants aids financial stability and promotes the adoption of sustainable agricultural solutions.
Negative Factors
Financial Instability
Ongoing financial challenges, including losses and liquidity constraints, threaten long-term viability and require strategic restructuring.
High Leverage
High leverage and negative equity indicate financial distress, limiting the company's ability to invest in growth and innovation.
Cash Flow Issues
Negative cash flows highlight liquidity problems, posing risks to operational sustainability and the ability to fund future initiatives.
Amoeba SA (ALMIB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€68.89M
Dividend YieldN/A
Average Volume (3M)268.33K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS Growth47.13%
CountryFR
Employees20
SectorServices
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,919,250
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-4.39
Price to Sales (P/S)75.97
P/FCF Ratio-9.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amoeba SA Business Overview & Revenue Model
Company DescriptionAmoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protection. The company was founded in 2010 and is headquartered in Chassieu, France.
How the Company Makes MoneyAmoeba SA generates revenue primarily through the sale of its biofertilizer and biopesticide products to farmers and agricultural distributors. The company operates a direct sales model, complemented by strategic partnerships with agricultural cooperatives and distribution networks to expand its market reach. Key revenue streams include product sales, licensing agreements for its proprietary technology, and collaborations with research institutions for the development of new microbial solutions. Additionally, Amoeba benefits from government subsidies and grants aimed at promoting sustainable agriculture, which further supports its earnings.
Amoeba SA Financial Statement Overview
Summary
Amoeba SA is facing significant financial challenges across all verticals. The income statement shows persistent losses, the balance sheet reflects high leverage and negative equity, and cash flow statements indicate liquidity issues. The company needs strategic restructuring to improve financial health and operational efficiency.Income Statement
Amoeba SA's income statement reveals significant challenges, with negative gross and net profit margins indicating the company is not currently profitable. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. The revenue growth rate is marked as 'Infinity' due to a low base effect, which does not provide a reliable growth trajectory.10
Very Negative
Balance Sheet
The balance sheet shows a concerning financial structure with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is negative, highlighting high leverage and financial instability. Return on equity is positive due to negative equity, which is not a positive indicator. Overall, the balance sheet suggests financial distress.15
Very Negative
Cash Flow
Cash flow analysis indicates negative operating and free cash flows, suggesting liquidity issues. The free cash flow to net income ratio is above 1, which is misleading due to negative net income. The company struggles to generate cash from operations, posing a risk to sustainability.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 601.60K | 601.60K | 664.31K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.11M | -805.57K | -1.71M | -1.01M | -858.95K | -1.47M |
| EBITDA | -5.63M | -5.38M | -13.74M | -5.35M | -5.01M | -5.05M |
| Net Income | -7.36M | -6.59M | -14.30M | -8.02M | -7.82M | -8.16M |
Balance Sheet | ||||||
| Total Assets | 6.37M | 5.65M | 6.29M | 12.39M | 14.50M | 13.06M |
| Cash, Cash Equivalents and Short-Term Investments | 741.84K | 458.94K | 519.33K | 5.53M | 7.28M | 4.97M |
| Total Debt | 16.77M | 12.07M | 4.92M | 2.36M | 12.50M | 8.62M |
| Total Liabilities | 20.64M | 16.06M | 10.23M | 4.23M | 14.30M | 11.06M |
| Stockholders Equity | -14.27M | -10.41M | -3.94M | 8.16M | 213.68K | 2.04M |
Cash Flow | ||||||
| Free Cash Flow | -6.07M | -4.78M | -12.59M | -5.71M | -6.05M | -3.52M |
| Operating Cash Flow | -4.38M | -4.22M | -6.50M | -5.40M | -5.90M | -3.46M |
| Investing Cash Flow | -1.65M | -2.01M | -2.81M | -212.13K | -140.65K | -76.93K |
| Financing Cash Flow | 6.19M | 6.16M | 4.30M | 3.87M | 4.98M | 3.54M |
Amoeba SA Technical Analysis
Positive
1.08
Price Trends
0.96
Positive
0.98
Positive
0.97
Positive
Market Momentum
0.01
Negative
54.64
Neutral
45.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMIB, the sentiment is Positive. The current price of 1.08 is above the 20-day moving average (MA) of 0.98, above the 50-day MA of 0.96, and above the 200-day MA of 0.97, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.64 is Neutral, neither overbought nor oversold. The STOCH value of 45.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALMIB.
Amoeba SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:ALMIB
Amoeba SA
1.00
0.16
19.47%
DE:4ZF
Orege SA
0.24
-0.13
-35.69%
FR:ARTE
Artea SA
7.75
-2.55
-24.76%
FR:MLCAN
Eurolog Canola Socimi SAU
―
―
―
FR:GRVO
Voltz (Graines)
18.90
-0.25
-1.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.